AAMI TIR57 vs TIR97: Medical Device Risk Management Guide

Compare AAMI TIR57 vs TIR97. Learn how these cybersecurity risk management standards differ and how to apply them for FDA premarket and postmarket compliance.

This guide is written for medical device manufacturers navigating AAMI TIR57 vs TIR97. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist.

Intro: The Ecosystem of Medical Device Risk Management

Intro: The Ecosystem of Medical Device Risk Management is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Why TIR57 and TIR97 Matter for FDA Submissions

Why TIR57 and TIR97 Matter for FDA Submissions — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

The Relationship with ISO 14971

The Relationship with ISO 14971 — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Deep Dive: AAMI TIR57 (Premarket Security)

Deep Dive: AAMI TIR57 (Premarket Security) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Core Principles of Security Risk Management

Core Principles of Security Risk Management — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Establishing the Security Risk Management Process

Establishing the Security Risk Management Process — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Impact on Product Design and Threat Modeling

Impact on Product Design and Threat Modeling — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Deep Dive: AAMI TIR97 (Postmarket Security)

Deep Dive: AAMI TIR97 (Postmarket Security) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Managing Risks Throughout the Product Lifecycle

Managing Risks Throughout the Product Lifecycle — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Vulnerability Disclosure and Intake Mechanisms

Vulnerability Disclosure and Intake Mechanisms — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Coordinated Vulnerability Disclosure (CVD) Integration

Coordinated Vulnerability Disclosure (CVD) Integration — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Direct Comparison: TIR57 vs TIR97

Direct Comparison: TIR57 vs TIR97 is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Key Process Differences

Key Process Differences — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Documentation Requirements: Pre- vs Postmarket

Documentation Requirements: Pre- vs Postmarket — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

When to Transition from TIR57 to TIR97 Guidance

When to Transition from TIR57 to TIR97 Guidance — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Best Practices for Implementing Both Standards

Best Practices for Implementing Both Standards is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Building a Unified Security Risk Management File

Building a Unified Security Risk Management File — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Integrating TIR Guidance into your Quality Management System (QMS)

Integrating TIR Guidance into your Quality Management System (QMS) — make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Conclusion: Ensuring Total Lifecycle Cybersecurity

Conclusion: Ensuring Total Lifecycle Cybersecurity is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

How Blue Goat Cyber Approaches AAMI TIR57 vs TIR97

We treat AAMI TIR57 vs TIR97 as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 250+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end:

• Scoping against your device profile. We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform.
• Standards mapping in writing. Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess.
• Evidence generated inside your QMS. Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit.
• Independent testing where it counts. Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices.
• Deficiency-ready posture. We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle.
• Postmarket handoff, not abandonment. Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance.

If you want that treatment applied to your AAMI TIR57 vs TIR97 package, our FDA Premarket Cybersecurity Services and FDA Cybersecurity Deficiency Response engagements are the two most common entry points.

Frequently asked questions

What is the difference between AAMI TIR57 and TIR97?

Short answer: AAMI TIR57 vs TIR97 is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below — every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Do I need both AAMI TIR57 and TIR97 for FDA compliance?

Short answer: Yes — under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below — every answer here is grounded in current FDA guidance and the standards your reviewer is using.

How does AAMI TIR57 relate to ISO 14971?

Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below — every answer here is grounded in current FDA guidance and the standards your reviewer is using.

What are the postmarket reporting requirements in AAMI TIR97?

Short answer: AAMI TIR57 vs TIR97 is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below — every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Which standard should I use for threat modeling medical devices?

Short answer: It depends on the device classification, intended use, and connectivity profile — but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below — every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Is AAMI TIR57 required for 510(k) submissions?

Short answer: It depends on the device classification, intended use, and connectivity profile — but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below — every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Where this fits in the cluster

This page sits downstream of our pillar resources on AAMI TIR57 vs TIR97. If you arrived here from a different starting point, these are the most useful adjacent pages:

• The MedTech Cybersecurity Standards Decoder
• The Postmarket Cybersecurity Readiness Plan
• FDA Premarket Cybersecurity Services
• FDA Postmarket Cybersecurity Services
• The SPDF Playbook for FDA-Ready Medical Devices

Related from Blue Goat Cyber

• Medical Device Threat Modeling
• Secure MedTech Product Design Consulting
• FDA Premarket Cybersecurity Services
• FDA Postmarket Cybersecurity Services
• 12 Critical Threat Modeling Gaps in Medical Device Submissions
• Glossary

Sources & primary references

• AAMI TIR57:2016 Principles for medical device security—Risk management — AAMI (Association for the Advancement of Medical Instrumentation)
• AAMI TIR97:2019/R2023 Principles for medical device security—Postmarket risk management for device manufacturers — AAMI (Association for the Advancement of Medical Instrumentation)
• Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions — U.S. Food and Drug Administration (FDA)
• Postmarket Management of Cybersecurity in Medical Devices — U.S. Food and Drug Administration (FDA)
• ISO 14971:2019 Medical devices — Application of risk management to medical devices — International Organization for Standardization (ISO)

Talk to a regulatory cybersecurity team

If you are working through AAMI TIR57 vs TIR97 and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. Book a discovery session and we will walk your evidence with you.